Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.66 USD
Change Today -0.18 / -2.30%
Volume 1.6M
KERX On Other Exchanges
Symbol
Exchange
KERX is not on other exchanges.
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

keryx biopharmaceuticals (KERX) Snapshot

Open
$7.85
Previous Close
$7.84
Day High
$8.02
Day Low
$7.29
52 Week High
08/28/14 - $18.48
52 Week Low
07/27/15 - $7.29
Market Cap
793.5M
Average Volume 10 Days
1.9M
EPS TTM
$-1.34
Shares Outstanding
103.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KERYX BIOPHARMACEUTICALS (KERX)

keryx biopharmaceuticals (KERX) Related Bloomberg News

View More Bloomberg News

keryx biopharmaceuticals (KERX) Related Businessweek News

No Related Businessweek News Found

keryx biopharmaceuticals (KERX) Details

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company also has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

156 Employees
Last Reported Date: 05/4/15
Founded in 1997

keryx biopharmaceuticals (KERX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $358.3K
Chief Financial Officer and Treasurer
Total Annual Compensation: $348.3K
Compensation as of Fiscal Year 2014.

keryx biopharmaceuticals (KERX) Key Developments

Keryx Receives CHMP Positive Opinion for Fexeric(R) (Ferric Citrate Coordination Complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease

Keryx Biopharmaceuticals Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ferric citrate coordination complex (EU approved brand name Fexeric) recommending approval for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease (CKD). Fexeric was approved under the brand name Auryxia by the U.S. Food and Drug Administration in September 2014, and is indicated in the U.S. for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union (EU) and Iceland, Norway and Liechtenstein. The EC generally follows the recommendation of the CHMP and typically issues its final opinion approximately two to three months following CHMP opinion. Keryx expects to make a decision about its EU commercial strategy by the end of 2015. Data Supporting Positive Opinion: The CHMP opinion is based on evidence from approximately 1900 patients, including two key clinical trials: a Phase 2, non-dialysis study and a 58-week, Phase 3 registration trial. In the Phase 3 trial, ferric citrate effectively reduced serum phosphorus levels to well within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL. These data were published in 2014 in the Journal of the American Society of Nephrology.

Keryx Announces Two National Insurance Providers Add Auryxia(TM) to Their Medicare Part D Formularies

Keryx Biopharmaceuticals Inc. announced that two national insurance providers have added Auryxia to their Medicare Part D formularies. Auryxia is the first and only absorbable, iron-based phosphate binder for the treatment of elevated serum phosphorus levels in people with chronic kidney disease on dialysis. Together, these new formularies will increase unrestricted access to Auryxia, across Medicare Part D and commercial insurance providers, to approximately 65% of people in the U.S. currently taking phosphate binders.

Keryx Biopharmaceuticals Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 02:30 PM

Keryx Biopharmaceuticals Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 02:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KERX:US $7.66 USD -0.18

KERX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KERX.
View Industry Companies
 

Industry Analysis

KERX

Industry Average

Valuation KERX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 394.2x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 321.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KERYX BIOPHARMACEUTICALS, please visit www.keryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.